Genzyme targets biosurgery in deal worth up to $900 million
This article was originally published in Clinica
Genzyme is to accelerate its efforts in biosurgery through the formation of a new company. It plans to merge two of its divisions and to buy Biomatrix, which it will then incorporate into the single unit to form separately-traded Genzyme Biosurgery. The new company will focus on the high-growth areas of bio-orthopaedics and cardiothoracic surgery.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.